Cirrhosis as a risk factor for venous thrombosis

Ton Lisman; Francesco Violi

doi:10.1160/TH16-10-0782

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2017; 117(01): 03-05
DOI: 10.1160/TH16-10-0782

Invited Editorial Focus

Schattauer GmbH

Cirrhosis as a risk factor for venous thrombosis

Autor*innen

Ton Lisman

¹Surgical Research Laboratory, Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Francesco Violi

²Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy

Abstract

Volltext

Referenzen

References
1 Lewis JH, Bontempo FA, Cornell F. et al. Blood use in liver transplantation. Transfusion 1987; 27: 222-225.
2 Garcia-Tsao G, Bosch J. Management of varices and variceal haemorrhage in cirrhosis. N Engl J Med 2010; 362: 823-832.
3 Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147-156.
4 Lisman T, Porte RJ. Rebalanced haemostasis in patients with liver disease: Evidence and clinical consequences. Blood 2010; 116: 878-885.
5 Kleinegris MC, Bos MH, Roest M. et al. Cirrhosis patients have a coagulopathy that is associated with decreased clot formation capacity. J Thromb Haemost 2014; 12: 1647-1657.
6 Violi F, Ferro D, Basili S. et al. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. the CALC group. coagulation abnormalities in liver cirrhosis. Hepatology 1993; 17: 78-83.
7 Martinez J, Palascak JE, Kwasniak D. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease. J Clin Invest 1978; 61: 535-538.
8 Raparelli V, Basili S, Carnevale R. et al. Low-grade endotoxemia and platelet activation in cirrhosis. Hepatology 2016 in press
9 Davi G, Ferro D, Basili S. et al. Increased thromboxane metabolites excretion in liver cirrhosis. Thromb Haemost 1998; 79: 747-751.
10 Gatt A, Riddell A, Calvaruso V. et al. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost 2010; 08: 1994-2000.
11 Saliola M, Lorenzet R, Ferro D. et al. Enhanced expression of monocyte tissue factor in patients with liver cirrhosis. Gut 1998; 43: 428-432.
12 Hugenholtz GC, Mccrae FL, Adelmeijer J. et al. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen. J Thromb Haemost 2016; 14: 1054-1066.
13 Northup PG, McMahon MM, Ruhl AP. et al. Co-agulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006; 101: 1524-1528.
14 Sogaard KK, Horvath-Puho E, Gronbaek H. et al. Risk of venous thromboembolism in patients with liver disease: A nationwide population-based case-control study. Am J Gastroenterol 2009; 104: 96-101.
15 Ferro D, Quintarelli C, Lattuada A. et al. High plasma levels of von willebrand factor as a marker of endothelial perturbation in cirrhosis: Relationship to endotoxemia. Hepatology 1996; 23: 1377-1383.
16 Vairappan B. Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress. World J Hepatol 2015; 07: 443-459.
17 Ambrosino P, Tarantino L, Di Minno G. et al. The risk of venous thromboembolism in patients with cirrhosis: A systematic review and meta-analysis. Thromb Haemost 2017; 117: 139-148.
18 Ioannidis JP. The mass production of redundant, misleading, and conflicted systematic reviews and meta-analyses. Milbank Q 2016; 94: 485-514.
19 Hugenholtz GC, Northup PG, Porte RJ. et al. Is there a rationale for treatment of chronic liver disease with antithrombotic therapy?. Blood Rev 2015; 29: 127-136.
20 Shatzel J, Dulai PS, Harbin D. et al. Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: A single-center retrospective cohort study. J Thromb Haemost 2015; 13: 1245-1253.
21 Gomez Cuervo C, Bisbal Pardo O, Perez-Jacoiste Asin MA. Efficacy and safety of the use of heparin as thromboprophylaxis in patients with liver cirrhosis: A systematic review and meta-analysis. Thromb Res 2013; 132: 414-419.
22 Moorehead KJ, Jeffres MN, Mueller SW. A retrospective cohort analysis of pharmacologic VTE prophylaxis and padua prediction score in hospitalized patients with chronic liver disease. J Pharm Pract 2016 in press
23 Intagliata NM, Henry ZH, Shah N. et al. Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding. Liver Int 2014; 34: 26-32.
24 Potze W, Arshad F, Adelmeijer J. et al. Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis. PLoS One 2014; 09: e88390.
25 Potze W, Arshad F, Adelmeijer J. et al. Routine coagulation assays underestimate levels of anti-thrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis. Br J Haematol 2013; 163: 666-673.
26 Bogari H, Patanwala AE, Cosgrove R, Katz M. Risk-assessment and pharmacological prophylaxis of venous thromboembolism in hospitalized patients with chronic liver disease. Thromb Res 2014; 134: 1220-1223.
27 Husted S, de Caterina R, Andreotti F. et al. ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost 2014; 111: 781-782.
28 Lisman T, Kamphuisen PW, Northup PG, Porte RJ. Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats. J Hepatol 2013; 59: 358-366.
29 Potze W, Adelmeijer J, Lisman T. Decreased in vitro anticoagulant potency of rivaroxaban and apixaban in plasma from patients with cirrhosis. Hepatology 2015; 61: 1435-1436.
30 Intagliata N, Maitland H, Northup P, Caldwell S. Treating thrombosis in cirrhosis patients with new oral agents: Ready or not?. Hepatology 2015; 61: 738-739.
31 De Gottardi A, Trebicka J, Klinger C. et al. Anti-thrombotic treatment with direct-acting oral anticoagulants (DOACs) in patients with splanchnic vein thrombosis and cirrhosis. Liver Int 2016;
32 Intagliata NM, Henry ZH, Maitland H. et al. Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci 2016; 61: 1721-1727.
33 Ferro D, Basili S, Lattuada A. et al. Systemic clotting activation by low-grade endotoxaemia in liver cirrhosis: A potential role for endothelial proco-agulant activation. Ital J Gastroenterol Hepatol 1997; 29: 434-440.
34 Violi F, Ferro D, Basili S. et al. Ongoing prothrombotic state in the portal circulation of cirrhotic patients. Thromb Haemost 1997; 77: 44-47.
35 Thalheimer U, Triantos CK, Samonakis DN. et al. Infection, coagulation, and variceal bleeding in cirrhosis. Gut 2005; 54: 556-563.
36 Warnaar N, Lisman T, Porte RJ. The two tales of coagulation in liver transplantation. Curr Opin Organ Transplant 2008; 13: 298-303.